In vitro antibacterial activity of garenoxacin

Japanese Journal of Chemotherapy

Volumn 55, Issue , 2007, Pages 1-20

  Takahata, Masahiro ^a   Fukuda, Yoshiko ^a   Futakuchi, Naoko ^a   Sugiura, Yoko ^a   Hisada, Harumi ^a   Mizunaga, Shingo ^a   Oogake, Naoko ^a   Ito, Yuko ^a   Shinmura, Yuko ^a   Nakatani, Masatoshi ^a   Tanaka, Tomoaki ^a   Komeno, Takashi ^a   Kamiyama, Tomoko ^a   Mitsuyama, Junichi ^a   Todo, Yozo ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

antimicrobial activity; garenoxacin; in vitro

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; GARENOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MINOCYCLINE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; TETRACYCLINE; TOSUFLOXACIN;

AEROBIC BACTERIUM; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIUM ISOLATION; CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE; DRUG POTENCY; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN CELL; IN VITRO STUDY; INOCULATION; KLEBSIELLA PNEUMONIAE; LEGIONELLA; LEGIONELLA PNEUMOPHILA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PENICILLIN RESISTANCE; PENICILLIN RESISTANT STREPTOCOCCUS PNEUMONIAE; PH; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 35349020580     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: 10.11250/chemotherapy1995.55.Supplement1_1     Document Type: Article

References (16)

1. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, et. al. : In vitro and In vivo antimicrobial activities of T-3811 ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999; 43 : 1077-84
2. Fung-Tomc J C, Minassian B, Kolek B, Huczko E, Aleksunes L, Stickle T, et. al. : Antibacterial spectrum of a novel des-fluoro (6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000; 44 : 3351-6
3. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Fourteenth Informational Supplement M100-S14. National Committee for Clinical Laboratory Standards, Wayne, Pa, 2004; 104-22
4. National Committee for Clinical Laboratory Standards. Methods for Dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard-Sixth Edition, M 7-A 6. National Committee for Clinical Laboratory Standards, Wayne, Pa, 2003
5. Ince D, Zhang X, Silver L C, Hooper D C : Dual targeting of DNA gyrase and topoisomerase IV : target interactions of garenoxacin (BMS-284756, T-3811-ME), a new desfluoroquinolone. Antimicrob Agents Chemother 2002; 46 : 3370-80
6. Ameyama S, Shinmura Y, Takahata M : Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae. Antimicrob Agents Chemother 2003; 47 : 2327-9
7. Schmitz F J, Boos M, Mayer S, Jagusch H, Fluit A C : Increased in vitro activity of the novel des-fluoro (6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2002; 49 : 283-7
8. Korzheva N, Davies T A, Goldschmidt R : Novel Ser-79 Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates. Antimicrob Agents Chemother 2005; 49 : 2479-86
9. Waites K B, Crabb D M, Bing X, Duffy L B : In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplas-mas. Antimicrob Agents Chemother 2003; 47 : 161-5
10. Malay S, Roblin P M, Reznik T, Kutlin A, Ham-merschlag M R : In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2002; 46 : 517-8
11. Blondeau J, Metzler K, Hansen G, Hedlin P, Borsos S : Determination of the minimal inhibitory concentration (MIC) and mutation prevention concentration (MPC) for garenoxacin against clinical isolates of Streptococcus pneumoniae. 13th European Congress of Clinical Microbiology and Infectious Diseases; 2003 May 10-3; Glasgow, UK
12. Zhao X, Eisner W, Perl-Rosenthal N, Kreiswirth B, Drlica K : Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47 : 1023-7
13. Li X, Mariano N, Rahal J J, Urban C M, Drlica K : Quinolone-resistant Haemophilus influenzae : determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother 2004; 48 : 4460-2
14. Andes D, Craig W A : Pharmacodynamics of the new des-F (6)-quinolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother 2003; 47 : 3935-41
15. Lister P D : Impact of AUC/MIC ratios on the pharmacodynamics of the des-F (6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J Antimicrob Chemother 2003; 51 : 199-202
16. Ambrose P G, Grasela D M, Grasela T H, Passarell J, Mayer H B, Pierce P F : Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45 : 2793-7